[ACC2012]NCDR获益与局限——Dr John A. Dodson专访
美国国家心血管注册研究(the National Cardiovascular DataRegistry,NCDR)是在ACC及相关学会基金资助下联合进行的一系列注册研究的统称。《国际循环》对来自Columbia University Medical Center的Dr John A. Dodson进行了专访。
美国国家心血管注册研究(the National Cardiovascular DataRegistry,NCDR)是在ACC及相关学会基金资助下联合进行的一系列注册研究的统称。《国际循环》对来自Columbia University Medical Center的Dr John A. Dodson进行了专访。
<International Circulation>: The NCDR Registry is very significant. What is it helping us learn?
《国际循环》: NCDR注册研究非常重要。这项研究对我们有何帮助?
Dr Dodson: Our study was with the NCDR ICD Registry which was one of the first registries to come out. The particular advantage of the ICD Registry is that every patient who is a Medicare beneficiary has data that is submitted. So we have a population of everybody who is in Medicare, but also 78% of patients, whether they are on Medicare or non-Medicare, under 65 or over 65,have data submitted to the registry. So it is by no means comprehensive or represents the entire United States, but we know we have data for everybody over 65 and everybody who gets a primary prevention-type device. It is very powerful in that we have a very large number of patients and it is at least mandated that patients who are insured by Medicare and who have primary prevention-type devices, have data that is submitted to the registry.
Dr Dodson: 我们的研究与NCDR ICD注册研究结果一致,后者是第一项公布结果的注册研究。ICD注册研究的突出优势在于每一例作为保险受益人的患者都会提交数据。由此我们的研究人群包括了所有保险受益的患者,此外还有78%的受试者,不论是否保险受益人,不论年龄低于或高于65岁,都向注册研究提交了数据;因此,该研究不够全面,也不能代表整个美国人群,但我们有了65岁以上以及接受了一级预防装置植入的患者数据。我们有了非常大的患者数量,患者受到医疗保险的保护而接受了一级预防装置植入,从这些角度而言这是很强的证据。